GlassScriptPhysician profile
Ryan B Sanford
NPI 1467653196
$3,635.98
in general payments reported to CMS, 2019-2025
34 companies · $895 in 2025
The $895 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $326 · 2021: $298 · 2022: $322 · 2023: $497 · 2024: $874 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $504.60 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $377.96 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $366.09 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $300.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $209.66 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $206.21 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $197.13 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $148.08 | 2019-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $133.04 | 2024-2025 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $124.14 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $110.76 | 2021-2025 | |
| Travere Therapeutics, INC. | $89.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.89 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $81.44 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $76.52 | 2023-2024 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $74.49 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $61.87 | 2021-2024 | Lupkynis |
| Ardelyx, INC. | $59.42 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $56.20 | 2019-2023 | Injectafer |
| Akebia Therapeutics INC | $49.30 | 2019-2022 | |
| Genzyme Corporation | $47.88 | 2019 | |
| Calliditas Therapeutics US INC. | $36.12 | 2025 | Tarpeyo |
| Lilly USA, LLC | $34.52 | 2023-2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $28.98 | 2019 | |
| Cormedix INC. | $26.48 | 2024 | Defencath |
| Scpharmaceuticals INC. | $20.70 | 2025 | |
| Apellis Pharmaceuticals, INC. | $17.81 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2020 | |
| Recordati_rare_diseases_inc. | $16.88 | 2025 | Cystadrops |
| Alnylam Pharmaceuticals INC. | $16.20 | 2025 | Onpattro |
| Kyowa Kirin, INC. | $15.57 | 2023 | Crysvita |
| Shield Therapeutics INC | $15.13 | 2023 | Accrufer |
| Leadiant Biosciences, INC. | $14.35 | 2025 | Cystaran |
| La Jolla Pharmaceutical Company | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.